ArticleiMeta2026
Bazi Bushen Capsule restores fertility by targeting mitochondrial health in aging endometrium.
Article in iMeta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Age-related decline in endometrial function is a major cause of fertility issues in women, but effective treatments are lacking. This study aimed to investigate the impact of Bazi Bushen Capsule (BZBS) on endometrial aging and its underlying mechanisms. Using naturally aged mice and d-galactose-induced senescent human endometrial stromal cell lines, along with primary human endometrial stromal cells, we explored the effects of BZBS through single-cell RNA sequencing, transcriptome analysis, network pharmacology, and molecular dynamics simulations. Our results showed that BZBS improved endometrial receptivity, and decidualization by activating the AMPK-SIRT3 pathway. The key bioactive components of BZBS were identified as ginsenosides Rb1, Rb2, Rg5, and luteolin. Specifically, luteolin restored mitochondrial homeostasis by regulating PINK1/Parkin-mediated mitophagy and inhibiting Drp1. These findings suggested that BZBS effectively restored endometrial function and offered a promising therapeutic approach to counteract age-related endometrial dysfunction, potentially improving fertility in women of advanced maternal age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.